Arcutis Biotherapeutics (ARQT) EBT (2019 - 2026)

Arcutis Biotherapeutics' EBT history runs 8 years deep, the most recent figure standing at -$11.2 million for Q1 2026.

• In Q1 2026, EBT rose 54.8% year-over-year to -$11.2 million; the TTM figure through Mar 2026 stood at -$1.4 million (up 98.92% YoY), while the FY2025 annual figure was -$15.0 million, up 89.26% from the prior year.
• EBT for Q1 2026 stood at -$11.2 million, down from $17.9 million in the prior quarter.
• The five-year high for EBT was $17.9 million in Q4 2025, with the low at -$107.7 million in Q3 2022.
• The 5-year median for EBT is -$41.7 million (2023), against an average of -$43.4 million.
• The sharpest annual moves came in 2022 and 2025: EBT plunged 88.76% in 2022, then soared 270.71% in 2025.
• Arcutis Biotherapeutics' EBT stood at -$72.0 million in 2022, then grew by 8.0% to -$66.3 million in 2023, then jumped by 84.21% to -$10.5 million in 2024, then jumped by 270.71% to $17.9 million in 2025, then plunged by 162.7% to -$11.2 million in 2026.
• Business Quant data shows ARQT's EBT at -$11.2 million in Q1 2026, $17.9 million in Q4 2025, and $7.5 million in Q3 2025.